BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 26645279)

  • 1. Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    Lacombe L; Fradet V; Lévesque É; Pouliot F; Larue H; Bergeron A; Hovington H; Caron A; Nguile-Makao M; Harvey M; Fradet Y; Guillemette C
    Cancer Prev Res (Phila); 2016 Feb; 9(2):189-95. PubMed ID: 26645279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
    Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
    Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer.
    Li HM; Azhati B; Rexiati M; Wang WG; Li XD; Liu Q; Wang YJ
    Int Urol Nephrol; 2017 Jan; 49(1):69-76. PubMed ID: 27766490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refraining from Smoking for 15 Years or More Reduced the Risk of Tumor Recurrence in Non-muscle Invasive Bladder Cancer Patients.
    Ogihara K; Kikuchi E; Yuge K; Ito Y; Tanaka N; Matsumoto K; Miyajima A; Asakura H; Oya M
    Ann Surg Oncol; 2016 May; 23(5):1752-9. PubMed ID: 26671037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism of glutathione S-transferases M1 and T1 as a risk factor in lung and bladder cancers.
    Salagovic J; Kalina I; Stubna J; Habalová V; Hrivnák M; Valanský L; Kohút A; Biros E
    Neoplasma; 1998; 45(5):312-7. PubMed ID: 9921921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients.
    Kang HW; Song PH; Ha YS; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Moon SK; Kim WJ
    Eur J Cancer; 2013 Sep; 49(14):3010-9. PubMed ID: 23810248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China.
    Song DK; Xing DL; Zhang LR; Li ZX; Liu J; Qiao BP
    Cancer Detect Prev; 2009; 32(5-6):416-23. PubMed ID: 19303722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer.
    Carta A; Pavanello S; Mastrangelo G; Fedeli U; Arici C; Porru S
    Int J Environ Res Public Health; 2018 Jul; 15(8):. PubMed ID: 30042310
    [No Abstract]   [Full Text] [Related]  

  • 11. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women.
    McGrath M; Michaud D; De Vivo I
    BMC Cancer; 2006 Oct; 6():239. PubMed ID: 17026750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between glutathione S-transferase M1 and T1 polymorphisms and increased risk for bladder cancer in Korean smokers.
    Jong Jeong H; Jin Kim H; Young Seo I; Ju Kim H; Oh GJ; Cheon Chae S; Sik Lim J; Taeg Chung H; Joong Kim J
    Cancer Lett; 2003 Dec; 202(2):193-9. PubMed ID: 14643449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
    Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
    Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do smoking and polymorphisms in xenobiotic metabolizing enzymes affect the histological stage and grade of bladder tumors?
    Ouerhani S; Rouissi K; Marrakchi R; Riadh Ben Slama M; Sfaxi M; Ayed M; Chebil M; Elgaaied A
    Bull Cancer; 2009 May; 96(5):E23-9. PubMed ID: 19467981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
    García-Closas M; Malats N; Silverman D; Dosemeci M; Kogevinas M; Hein DW; Tardón A; Serra C; Carrato A; García-Closas R; Lloreta J; Castaño-Vinyals G; Yeager M; Welch R; Chanock S; Chatterjee N; Wacholder S; Samanic C; Torà M; Fernández F; Real FX; Rothman N
    Lancet; 2005 Aug 20-26; 366(9486):649-59. PubMed ID: 16112301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic deletions of the GSTT1 and GSTM1 genes and susceptibility to bladder cancer.
    Salinas-Sánchez AS; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-del-Campo A; Gimenez-Bachs JM; Lorenzo-Romero JG; Serrano-Oviedo L; Escribano J
    BJU Int; 2011 Jun; 107(11):1825-32. PubMed ID: 20942828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of oncostatin M receptor gene polymorphisms in bladder cancer.
    Deng S; He SY; Zhao P; Zhang P
    World J Surg Oncol; 2019 Feb; 17(1):30. PubMed ID: 30755233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number variations of GSTT1 and GSTM1, colorectal cancer risk and possible effect modification of cigarette smoking and menopausal hormone therapy.
    Rudolph A; Hein R; Hoffmeister M; Försti A; Hemminki K; Risch A; Brenner H; Chang-Claude J
    Int J Cancer; 2012 Sep; 131(5):E841-8. PubMed ID: 22234881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glutathione S-transferase mu1 and N-acetyltransferase 2 genetic polymorphisms and exposure to tobacco smoke in nonsmoking and smoking lung cancer patients and population controls.
    Nyberg F; Hou SM; Hemminki K; Lambert B; Pershagen G
    Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):875-83. PubMed ID: 9796632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.